Physician profile
Randall Frederick
NPI 1487656393
$7,718.39
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $203 · 2021: $264 · 2022: $2,188 · 2023: $1,946 · 2024: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,575 · Education: $64.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,575.18 |
| Education | $64.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,730.65 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,696.64 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $523.28 | 2019-2024 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $514.47 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Celgene Corporation | $455.50 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $313.17 | 2019-2024 | Ocaliva |
| Ferring Pharmaceuticals INC. | $281.59 | 2019-2023 | Rebyota |
| Genzyme Corporation | $273.87 | 2022-2024 | |
| Qol Medical, LLC | $231.78 | 2021-2024 | Sucraid |
| Nestle Healthcare Nutrition INC. | $199.57 | 2021-2023 | |
| Gilead Sciences, INC. | $194.85 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $187.24 | 2019-2024 | Linzess |
| Pfizer INC. | $161.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $141.64 | 2022-2024 | Dificid |
| Lilly USA, LLC | $124.57 | 2023-2024 | Omvoh |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $75.34 | 2024 | Voquezna |
| Evoke Pharma, INC. | $68.66 | 2021-2024 | Gimoti |
| Celltrion USA INC. | $64.61 | 2024 | Zymfentra |
| Amag Pharmaceuticals, INC. | $64.41 | 2019-2022 | |
| Ardelyx, INC. | $64.29 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $61.16 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $56.33 | 2022-2023 | Dupixent |
| Amgen INC. | $54.84 | 2022-2023 | Amjevita |
| Boston Scientific Corporation | $29.51 | 2019-2022 | |
| Daiichi Sankyo INC. | $21.43 | 2023 | Injectafer |
| Shield Therapeutics INC | $17.26 | 2023 | Accrufer |
| Madrigal Pharmaceuticals | $16.10 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $15.92 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.20 | 2023 | Terlivaz |
| Janssen Scientific Affairs, LLC | $13.55 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.89 | 2019 | |
| Ucb, INC. | $12.82 | 2019 | |
| Shire North American Group INC | $11.87 | 2019 | |
| Redhill Biopharma INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.